Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096928 · ClinicalTrials.gov registry record
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
A clinical trial of Psoriasis, sponsored by Genentech.
- Completed
- Registry status
- 1,846
- Enrollment target
- 20
- Study locations
NCT00096928 is a study of Psoriasis that has completed, run by Genentech. The registered enrollment target is 1,846 participants, above the 474-participant average among 125 other Psoriasis trials with a reported enrollment target (289% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00096928, a study of Psoriasis, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 1,846 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.
Conditions Studied
Study Locations (20)
California
- Bakersfield Dermatology and Skin Cancer Medical Grp - Bakersfield
- T. Joseph Raoof, MD, Inc. - Encino
- Minarets Medical Group - Fresno
- Associates In Research, Inc. - Fresno
- Delta Dermatology Medical Group - Inglewood
- Fairmont Dermatology Medical Associates, Inc - Lodi
- Dermatology Associates - Los Angeles
- Elizabeth A. Abel, MD - Mountain View
- Dermatology Medical Group of Oxnard - Oxnard
- Kent Carson, MD - San Jose
- East Bay Psoriasis Treatment Center - San Ramon
Alabama
- Total Skin and Beauty Dermatology Center - Birmingham
- Deep South Dermatology - Daphne
- The Dermatology Center - Gadsden
- Medical Affiliated Research Center, Inc. - Huntsville
- Ruth A. Yates, MD - Huntsville
Arizona
- SunValley Arthritis Center Ltd - Glendale
- Alliance Dermatology and MOHS - Phoenix
Arkansas
- BGPDS Dermatology - Little Rock
- Hull Dermatology, PA - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,846 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096928
The ClinicalTrials.gov registry entry for NCT00096928 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,846 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 474-participant average among 125 other Psoriasis trials with a reported enrollment target (289% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT00096928 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00096928 about?
NCT00096928 is a clinical study titled "A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)". This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psor...
What is the current status of trial NCT00096928?
This trial is currently completed. The enrollment target is 1,846 participants. The study started on 2005-03. Estimated completion is 2009-10.
What conditions does trial NCT00096928 study?
This clinical trial studies the following conditions: Psoriasis.
Who is sponsoring clinical trial NCT00096928?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00096928 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.